Clinical Trial

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Investigator
Complete title:
A Randomized Trial for Patients with High-Grade Myeloid Neoplasms with Measurable Residual Disease (MRD): CPX-351 vs. Immediate Allogeneic Hematopoietic Cell Transplantation
Trial phase:
Phase II
Study ID:
NCT04526288
Local study ID:
RG1007476
Summary:
This phase II trial studies the effect of CPX-351 followed by donor stem cell transplantation versus immediate donor stem cell transplantation in treating patients with high-grade myeloid cancers with measurable residual disease. Chemotherapy drugs, such as CPX-351, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before donor stem cell transplantation may help kill cancer cells in the body and make room in the patient`s bone marrow for new blood-forming cells (stem cells) to grow.
Trial keywords:
Leukemia, Acute Myeloid (AML), Myelodysplastic Syndromes (MDS), Leukemia, Myeloid
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Contact us

For more information about Fred Hutch and to schedule an appointment.